This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration (GLY2)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Chiesi Farmaceutici S.p.A.
ClinicalTrials.gov Identifier:
NCT01176903
First received: August 5, 2010
Last updated: March 28, 2017
Last verified: March 2017
  Purpose
The purpose of this study is to evaluate the safety and the efficacy of Glycopyrrolate as pMDI after single and repeated administration.

Condition Intervention Phase
Chronic Obstructive Pulmonary Disease (COPD) Drug: Glycopyrrolate Drug: Tiotropium Drug: placebo Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Placebo-controlled, Cross-over Study to Investigate the Bronchodilator Efficacy and Safety After Single and Repeated Administrations of Different Doses of Glycopyrrolate Via pMDI in Moderate to Severe COPD Patients.

Resource links provided by NLM:


Further study details as provided by Chiesi Farmaceutici S.p.A.:

Primary Outcome Measures:
  • Safety [ Time Frame: Up to 24 hours after single administration ]

    Adverse events, vital signs, ECG parameters, 24-hours ECG holter recording, clinical laboratory abnormalities.

    This primary outcome is for the Part 1 of the study.


  • Lung function (trough FEV1) [ Time Frame: 12 hours post dose after repeated administration ]
    This primary variable is for the Part 2 of the study.


Secondary Outcome Measures:
  • Lung function [ Time Frame: up to 24 hours post dose ]
    for Part 1 of the study

  • Lung function (other parameters) [ Time Frame: up to 12 hours after repated administration ]
    for Part 2 of the study

  • Body plethysmography [ Time Frame: up tp 12 hours after repeated administration ]
    for Part 2 of the study

  • Pharmacokinetics [ Time Frame: up to 12 hours after single and repeated administration ]
    Pharmacokinetics in plasma and urine. For Part 2 of the study.

  • Safety [ Time Frame: up to 12 hours after single and repeated administration ]
    Adverse events, Vital signs, ECG parameters, 24-hour ECG holter recording. For Part 2 of the study.


Enrollment: 65
Study Start Date: August 2010
Study Completion Date: August 2011
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Glyco SD1
Single administration of Glyco pMDI dose level 1
Drug: Glycopyrrolate
pressurized metered dose inhaler
Other Name: CHF 5259
Experimental: Glyco SD2
Single administration of Glyco pMDI dose level 2
Drug: Glycopyrrolate
pressurized metered dose inhaler
Other Name: CHF 5259
Experimental: Glyco SD3
Single administration of Glyco pMDI dose level 3
Drug: Glycopyrrolate
pressurized metered dose inhaler
Other Name: CHF 5259
Experimental: Glyco SD4
Single administration of Glyco pMDI dose level 4
Drug: Glycopyrrolate
pressurized metered dose inhaler
Other Name: CHF 5259
Experimental: Glyco SD5
Single administration of Glyco pMDI dose level 5
Drug: Glycopyrrolate
pressurized metered dose inhaler
Other Name: CHF 5259
Placebo Comparator: Placebo SP
Single administration of Placebo pMDI
Drug: placebo
pressurized metered dose inhaler
Experimental: Glyco MD1
Multiple administration of Glyco pMDI dose level 1
Drug: Glycopyrrolate
pressurized metered dose inhaler
Other Name: CHF 5259
Experimental: Glyco MD2
Multiple administration of Glyco pMDI dose level 2
Drug: Glycopyrrolate
pressurized metered dose inhaler
Other Name: CHF 5259
Experimental: Glyco MD3
Multiple administration of Glyco pMDI dose level 3
Drug: Glycopyrrolate
pressurized metered dose inhaler
Other Name: CHF 5259
Placebo Comparator: Placebo MP
Multiple administration of placebo pMDI
Drug: placebo
pressurized metered dose inhaler
Active Comparator: Tiotropium
Multiple administration of tiotropium
Drug: Tiotropium
inhalation powder, hard capsule
Other Name: Spiriva

Detailed Description:

The study is divided into two parts:

- Part 1 will be conducted according to a single-centre, randomized, double-blind, placebo-controlled, single-dose escalation, alternating crossover design in two groups of COPD patients.

Treatments to be administered on Part 1 (SD1, SD2, SD3, SD4, SD5, SP). The primary objective of Part 1 is the evaluation of the safety and tolerability of Glyco after single administration.

- Part 2 will be conducted according to a single-centre, randomized, double-blind, placebo-controlled, 4-period, 4-treatment, repeated dose cross-over design followed by an open-label extension period with tiotropium.

Treatments administered on Part 2 (MD1, MD2, MD3, MP, Tiotropium). On the last treatment day in the morning, Formoterol 12 µg will be administered to all patients on top of placebo or Glyco or Tiotropium.

The primary objective of Part 2 is the evaluation of the efficacy of Glyco after repeated administration.

Part 2 will start after a safety review of the results obtained from Part 1.

  Eligibility

Ages Eligible for Study:   40 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and females patients aged 40-75 years;
  • Written informed consent obtained;
  • Diagnosis of moderate-severe COPD, according to the GOLD guidelines;
  • Current or ex-smokers with a smoking history of ≥ 10 pack-years
  • Post bronchodilator FEV1 between 40% and 80% predicted values (40% ≤ FEV1 < 80%), documented at screening visit ;
  • Post bronchodilator FEV1/Forced Vital Capacity (FEV1/FVC) ≤ 0.70 (absolute value) documented at screening visit;
  • Airway reversibility of at least 100 mL within 30 to 45 minutes after inhalation of ipratropium 80µg.

Exclusion Criteria:

  • History of chronic or seasonal allergy
  • Blood eosinophil count above 600 per µl
  • Clinically relevant findings on physical examination laboratory and ECG parameters at screening
  • Occurrence of clinically relevant abnormalities in the 24-h Holter ECG recording at screening;
  • Significant disease not related to COPD (eg. Myocardial infarction, stroke within the preceding 6 months);
  • Respiratory tract infection (including upper tract) 4 weeks prior to study entry requiring changing treatment;
  • Patients requiring oxygen therapy on a daily basis for chronic hypoxemia;
  • History of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency, or any other significant lung disease which is considered to be clinically significant by the investigator.
  • Intolerance/hypersensitivity or any contra-indication to treatment with M3 Antagonist or any of the excipients contained in the formulations used in the study.
  • History of alcohol or substance abuse that in the opinion of the Investigator may be of clinical significance.
  • Patients treated with slow-release oral or parental corticosteroids 8 weeks prior to Screening Visit.
  • Patients treated with tiotropium in the 10 days prior to the Screening Visit;
  • Pregnant or lactating women and female or male subjects not willing to use an acceptable method of contraception.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01176903

Locations
United Kingdom
Medicines Evaluation Unit
Manchester, United Kingdom, M23 9QZ
Sponsors and Collaborators
Chiesi Farmaceutici S.p.A.
Investigators
Principal Investigator: Dave Singh, MD Medicines Evaluation Unit Ltd
  More Information

Additional Information:
Responsible Party: Chiesi Farmaceutici S.p.A.
ClinicalTrials.gov Identifier: NCT01176903     History of Changes
Other Study ID Numbers: CCD-0916-PR-0032
2010-018668-18 ( EudraCT Number )
Study First Received: August 5, 2010
Last Updated: March 28, 2017

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Tiotropium Bromide
Glycopyrrolate
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Parasympatholytics
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adjuvants, Anesthesia
Muscarinic Antagonists

ClinicalTrials.gov processed this record on June 22, 2017